Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F14%3AE0104018" target="_blank" >RIV/00843989:_____/14:E0104018 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/14:A1501CGH

Result on the web

<a href="http://dx.doi.org/10.1016/S1470-2045(13)70609-0" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(13)70609-0</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/S1470-2045(13)70609-0" target="_blank" >10.1016/S1470-2045(13)70609-0</a>

Result language

angličtina

Original language name

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

Original language description

BACKGROUND: Lenalidomide has been linked to second primary malignancies in myeloma. We aimed to pool and analyse available data to compare the incidence of second primary malignancies in patients with and without lenalidomide exposure. METHODS: We identified relevant studies through a search of PubMed and abstracts from the American Society of Clinical Oncology, American Society of Hematology, and the International Myeloma Workshop. Randomised, controlled, phase 3 trials that recruited patients with newly diagnosed multiple myeloma between Jan 1, 2000, and Dec 15, 2012, and in which at least one group received lenalidomide were eligible for inclusion. We obtained individual patient data (age, sex, date of diagnosis, allocated treatment and received treatment, duration of treatment and cause of discontinuation, maintenance treatment, date of first relapse, date of second primary malignancy diagnosis, type of second primary malignancy, date of death or last contact, and cause of death) b

Czech name

—

Czech description

—

Type

J_x - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

CEP classification

FD - Oncology and haematology

OECD FORD branch

—

Project

—

Continuities

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Publication year

2014

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Lancet Oncology

ISSN

1470-2045

e-ISSN

—

Volume of the periodical

15

Issue of the periodical within the volume

n. 3

Country of publishing house

US - UNITED STATES

Number of pages

10

Pages from-to

"p. 333-342"

UT code for WoS article

000332399900044

EID of the result in the Scopus database

—